Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced a filing with the Respiratory Diseases Branch of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), to evaluate AT-100 (rhSP-D) as a therapeutic for the novel coronavirus (COVID-19).
CINCINNATI, March 11, 2020 /PRNewswire/ -- Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced a filing with the Respiratory Diseases Branch of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), to evaluate AT-100 (rhSP-D) as a therapeutic for the novel coronavirus (COVID-19). Airway is advancing AT-100 – an engineered version of an endogenous protein – that has been shown in preclinical studies to safely reduce inflammation and infection while modulating the immune response across a range of respiratory diseases inside and outside the lung. Airway is aiming to enter the clinic later this year with AT-100 as an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD) in very preterm infants. AT-100 has the potential to serve as an innovative therapy for the novel coronavirus by targeting critical stages of viral infection through:
“Research has demonstrated that rhSP-D plays a key role in the clearance of numerous bacteria and viruses across a range of serious respiratory diseases. As COVID-19 is a novel respiratory virus, it is important to follow the data to understand if AT-100 may be an effective therapeutic with prophylactic potential to reduce infection and inflammation in patients with COVID-19,” said Marc Salzberg, M.D., president and CEO of Airway. “The COVID-19 outbreak has illuminated the urgency to identify and explore new therapies for patients in need, and Airway is committed to partnering with the National Institutes of Health to explore and advance AT-100 as a potential therapeutic option.” About AT-100 About Coronavirus
About Airway Therapeutics View original content to download multimedia:http://www.prnewswire.com/news-releases/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus-301021166.html SOURCE Airway Therapeutics, Inc. |